After-Hours Stock Movers 10/20: (CERC) (ALKS) (PFPT) (MSFT) Higher; (SKX) (RRGB) (AMD) Lower (more...)
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Today's After-Hours Movers
Cerecor (NASDAQ: CERC) 55.9% HIGHER; surges on Alkermes positive trial results.
Alkermes plc (NASDAQ: ALKS) 37.9% HIGHER; announced positive topline results from FORWARD-5, the third phase 3 efficacy study to read out from the FORWARD pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. The study met its prespecified primary endpoint showing treatment with ALKS 5461 significantly reduced symptoms of depression in patients with MDD compared to placebo. ALKS 5461 was generally well tolerated. The most common adverse events observed for ALKS 5461 were nausea, dizziness and fatigue. Based on these results, along with the substantial data collected to date on the efficacy and safety of ALKS 5461 for the treatment of MDD, the company plans to request a meeting with the U.S. Food and Drug Administrations (FDA) Division of Psychiatric Products to discuss the filing strategy for this Fast Track designated medicine.
Skechers USA (NYSE: SKX) 15.3% LOWER; reported Q3 EPS of $0.42, $0.05 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $942.4 million versus the consensus estimate of $954.38 million. GUIDANCE: Skechers USA sees Q4 2016 revenue of $710-735 million, versus the consensus of $799.9 million.
Proofpoint (NASDAQ: PFPT) 9.7% HIGHER; reported Q3 EPS of $0.19, $0.14 better than the analyst estimate of $0.05. Revenue for the quarter came in at $99.8 million versus the consensus estimate of $94.27 million. GUIDANCE: Proofpoint sees Q4 2016 EPS of $0.10-$0.14, versus the consensus of $0.06. Proofpoint sees Q4 2016 revenue of $103-105 million, versus the consensus of $99.85 million. Proofpoint sees FY2016 EPS of $0.28-$0.33, versus the consensus of $0.09. Proofpoint sees FY2016 revenue of $371.7-373.7 million, versus the consensus of $363.06 million.
Red Robin Gourmet Burgers, Inc., (Nasdaq: RRGB) 7% LOWER; announced preliminary results for its fiscal third quarter ended October 2, 2016. The Company also revised its outlook for fiscal year 2016. The Company expects to report the following estimated financial results for the fiscal third quarter 2016: Total revenues of approximately $297 million (The Street sees revenue of $301.2 million.) Comparable restaurant revenue decrease of 3.6% Net loss of approximately $3.0 million or $0.23 per diluted share Adjusted net income of approximately $5.1 million or $0.38 per diluted share (excluding restaurant impairment and closure costs of $8.1 million, net of tax, or $0.61 per diluted share) (Consensus estimates called for EPS of $0.49.
Verisign Inc. (NASDAQ: VRSN) 7% HIGHER; Reports Amendments to Agreements with DOC, ICANN
Microsoft (NASDAQ: MSFT) 5.8% HIGHER; reported Q1 EPS of $0.76, $0.08 better than the analyst estimate of $0.68. Revenue for the quarter came in at $22.3 billion versus the consensus estimate of $21.71 billion.
Advanced Micro Devices (NASDAQ: AMD) 5.5% LOWER; reported Q3 operating EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $1.31 billion versus the consensus estimate of $1.21 billion. Guidance: For Q4 2016, AMD expects revenue to decrease 18 percent sequentially, plus or minus 3 percent. The midpoint of guidance would result in Q4 2016 revenue increasing approximately 12 percent year-over-year and 2016 revenue increasing 6 percent from 2015.
PTC Therapeutics, Inc. (Nasdq: PTCT) 5.4% HIGHER; announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche (OTC: RHHBY) and the SMA Foundation (SMAF) initiated a Phase 2 study in pediatric and adult Type 2/3 SMA patients. The study, named SUNFISH, is a two-part study investigating the safety, tolerability and efficacy of RG7916, an oral small molecule survival motor neuron 2 (SMN2) splicing modifier. The first part of the study will evaluate safety and tolerability through escalating doses of RG7916. After dose selection, the study will transition into the pivotal second part evaluating the efficacy of RG7916. Initiation of the pivotal second part of the study is expected to begin in 2017 and will trigger a $20 million milestone payment to PTC from Roche. A similarly designed two-part study to evaluate RG7916 in Type I SMA patients is expected to begin in the coming months. SMA is a rare genetic disorder that results in neuromuscular disability beginning in infancy and is the leading genetic cause of mortality in infants and young children.
DXP Enterprises, Inc. (Nasdaq: DXPE) 4.4% LOWER; announced the commencement of a primary public offering of 2,700,000 shares of its common stock. In connection with the offering, DXP intends to grant the underwriters a 30-day option to purchase an additional 405,000 shares of its common stock.
PayPal (NASDAQ: PYPL) 4.3% HIGHER; reported Q3 EPS of $0.35, in-line with the analyst estimate of $0.35. Revenue for the quarter came in at $2.67 billion versus the consensus estimate of $2.65 billion. GUIDANCE: PayPal sees Q4 2016 EPS of $0.40-$0.42, versus the consensus of $0.42. PayPal sees Q4 2016 revenue of $2.92-2.99 billion, versus the consensus of $2.97 billion. PayPal sees FY2016 EPS of $1.48-$1.50, versus the consensus of $1.50. PayPal sees FY2016 revenue of $10.78-10.85 billion, versus the consensus of $10.82 billion.
athenahealth (NASDAQ: ATHN) 3.7% LOWER; reported Q3 EPS of $0.60, $0.13 better than the analyst estimate of $0.47. Revenue for the quarter came in at $276.7 million versus the consensus estimate of $280.72 million. GUIDANCE: athenahealth sees FY2016 EPS of $1.65-$1.85, versus the consensus of $1.77. athenahealth sees FY2016 revenue of $1.085-1.115 billion, versus the consensus of $1.1 billion.
Apollo Education Group (NASDAQ: APOL) 3.2% HIGHER; reported Q4 EPS of $0.21, $0.26 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $492.5 million versus the consensus estimate of $471.57 million.
KLA-Tencor (NASDAQ: KLAC) 2.8% HIGHER; reported Q1 EPS of $1.16, $0.13 better than the analyst estimate of $1.03. Revenue for the quarter came in at $751 million versus the consensus estimate of $733.8 million.
E*TRADE Financial (NASDAQ: ETFC) 2% HIGHER; reported Q3 EPS of $0.51, $0.11 better than the analyst estimate of $0.40. Revenue for the quarter came in at $486 million versus the consensus estimate of $470.96 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA/Merrill Lynch Upgrades CF Industries (CF) to Buy, Says "Consensus Estimates Now Beatable"
- Signet Jewelers (SIG) May Be Close To Selling Credit Business, Likely Positive For Stock - Northcoast Research
- Citigroup Maintains Neutral On IBM (IBM) Following Q4 2016 Earnings Report
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesAfter-Hours Movers, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!